Editas Medicine (NASDAQ: EDIT)
Editas Medicine Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Editas Medicine Company Info
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
News & Analysis
1 Stock Down 97% That Could Double, According to Wall Street
Editas Medicine: A Cautionary Tale for Investors
The Best CRISPR Companies to Invest In
These CRISPR stocks could be big winners for patient investors.
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The company has great potential if and when it enters the commercial stage.
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner.
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The biotech has bounced back some in the past year.
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Valuation
Podcast Episodes
Earnings Transcripts
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
EDIT earnings call for the period ending September 30, 2021.
Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2021.
Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript
EDIT earnings call for the period ending March 31, 2021.
Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
EDIT earnings call for the period ending .
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.